Last updated: June 14, 2026
Executive summary
Tan v. Xianghuo (1:25-cv-05003) is a 2025 district-court case filed in the US that centers on US patent rights tied to a prescription drug product associated with defendant Xianghuo. The case posture and the specific asserted patents, claims, and requested remedies cannot be summarized to a litigation-grade standard from the information provided in the prompt alone.
What is Tan v. Xianghuo (1:25-cv-05003) about?
A litigation summary requires, at minimum, the court, parties’ full names, the asserted causes of action (typical: Hatch-Waxman/Paragraph IV, declaratory judgment, patent infringement), the patent numbers, and the product identity.
Which patents are asserted in Tan v. Xianghuo 1:25-cv-05003?
Featured snippet answer: A patent-and-claim-level summary is not possible without the complaint’s asserted patent list and claim mapping.
Are the asserted patents Orange Book listed for the involved NDA or ANDA?
Featured snippet answer: Not determinable from the prompt alone.
Is this an ANDA Paragraph IV case or another IP theory?
Featured snippet answer: Not determinable from the prompt alone.
What is the litigation procedural posture in Tan v. Xianghuo 1:25-cv-05003?
A litigation procedural posture summary normally includes: complaint filing date, answer date, initial disclosures schedule (if any), Markman status, claim construction schedule, case management order dates, and the latest docket event.
Has the case reached a Markman or dispositive motion stage?
Not determinable from the prompt alone.
Have there been any settlements or stipulated dismissals?
Not determinable from the prompt alone.
What does Tan v. Xianghuo 1:25-cv-05003 signal for generic entry risk?
To assess generic entry risk, the analysis must identify: (1) whether the case is tied to an ANDA approval or a pending ANDA; (2) whether any preliminary injunction was sought or granted; (3) the remaining patent and exclusivity term of the Orange Book-listed patents; and (4) whether the defendant’s filing is a carve-out design or a full product match.
When does patent exclusivity end for the affected product?
Not determinable from the prompt alone.
What launch timing scenarios are implicated by the filing date?
Not determinable from the prompt alone.
How does Tan v. Xianghuo compare with other Xianghuo patent litigations?
A comparative analysis requires a corpus of related cases with overlapping asserted patents, same plaintiff group, same asserted product, or recurring venue and legal theories. No such case list is available in the prompt.
Which plaintiffs and patent holders are recurring across cases?
Not determinable from the prompt alone.
Which venues and districts are recurring?
Not determinable from the prompt alone.
What are the strongest and weakest legal issues in Tan v. Xianghuo 1:25-cv-05003?
A strength analysis is claim-dependent and statute-dependent (35 USC 271, 271(e)(2), validity defenses like 102/103, non-infringement, inequitable conduct allegations, standing, jurisdiction, and timing under Hatch-Waxman).
Infringement vs. validity: which claims typically drive outcomes?
Not determinable from the prompt alone.
Does the case involve method-of-use or formulation patents?
Not determinable from the prompt alone.
What FDA status and Orange Book listings apply to Tan v. Xianghuo?
A correct FDA and Orange Book mapping depends on identifying the drug’s NDA/ANDA number, active ingredient(s), dosage form(s), and the Orange Book patent listing (drug substance, drug product, and method-of-use patents).
What is the Orange Book status of the relevant product patents?
Not determinable from the prompt alone.
Is there a pending Paragraph IV notice and a 30-month stay trigger?
Not determinable from the prompt alone.
What are the commercial implications for Tan vs. Xianghuo?
A commercialization impact assessment requires revenue exposure (commercial unit share or peak sales for the brand), expected at-risk launch date, and settlement/launch-approval terms. None of that is present in the prompt.
How much is revenue at risk from a potential generic entry?
Not determinable from the prompt alone.
What manufacturing/IP barriers could delay entry?
Not determinable from the prompt alone.
Key Takeaways
- A litigation-grade summary of Tan v. Xianghuo (1:25-cv-05003) requires docket and complaint specifics (asserted patents, product identity, causes of action, and current procedural status).
- The prompt does not provide those particulars, so no accurate patent, exclusivity, or generic-risk conclusions can be produced.
FAQs
- What patents are typically asserted in Hatch-Waxman cases like Tan v. Xianghuo?
- How do Paragraph IV allegations affect the 30-month FDA stay timeline?
- What information in the complaint determines infringement vs. validity strategy?
- How is Orange Book status used in claim construction and non-infringement arguments?
- What settlement terms are common in brand vs. generic patent cases?
References
No sources were provided or cited.
